Casting a wide clinical net has its drawbacks - cost, mainly - and its advantages, such as better chances of finding efficacy. But even the positive point isn't always entirely so, as Cytokinetics Inc. found out late last month, when its good/bad news regarding ispinesib, its kinesin spindle protein (KSP) inhibitor for cancer. (BioWorld Financial Watch) Read More
